Overview

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability of DC371739 Treatment in Hypercholesterolemic

Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
This study is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of DC739 after multiple-dose oral administration, to explore the clinical effective dose, and to initially explore the efficacy and safety in hypercholesterolemia subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Guangzhou JOYO Pharma Co., Ltd
Collaborator:
The First Hospital of Jilin University